JP7626773B2 - ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン - Google Patents

ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン Download PDF

Info

Publication number
JP7626773B2
JP7626773B2 JP2022542951A JP2022542951A JP7626773B2 JP 7626773 B2 JP7626773 B2 JP 7626773B2 JP 2022542951 A JP2022542951 A JP 2022542951A JP 2022542951 A JP2022542951 A JP 2022542951A JP 7626773 B2 JP7626773 B2 JP 7626773B2
Authority
JP
Japan
Prior art keywords
compound
cancer
salt
her2
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022542951A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512174A (ja
JPWO2021156178A5 (https=
JP2023512174A5 (https=
Inventor
ビルギット ワイルディング
ディートリッヒ ベーゼ
ハーラルト エンゲルハルト
ユリアン フックス
ラルフ ノイミュラー
マルク ペトロンスキ
ディルク シャルン
マティアス トロイ
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2023512174A publication Critical patent/JP2023512174A/ja
Publication of JPWO2021156178A5 publication Critical patent/JPWO2021156178A5/ja
Publication of JP2023512174A5 publication Critical patent/JP2023512174A5/ja
Application granted granted Critical
Publication of JP7626773B2 publication Critical patent/JP7626773B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022542951A 2020-02-03 2021-02-01 ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン Active JP7626773B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20155157.9 2020-02-03
EP20155157 2020-02-03
PCT/EP2021/052261 WO2021156178A1 (en) 2020-02-03 2021-02-01 [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors

Publications (4)

Publication Number Publication Date
JP2023512174A JP2023512174A (ja) 2023-03-24
JPWO2021156178A5 JPWO2021156178A5 (https=) 2024-02-08
JP2023512174A5 JP2023512174A5 (https=) 2024-02-08
JP7626773B2 true JP7626773B2 (ja) 2025-02-04

Family

ID=69467424

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542951A Active JP7626773B2 (ja) 2020-02-03 2021-02-01 ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン

Country Status (5)

Country Link
US (1) US20230126204A1 (https=)
EP (1) EP4100409B1 (https=)
JP (1) JP7626773B2 (https=)
CN (1) CN115052878B (https=)
WO (1) WO2021156178A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11608343B2 (en) * 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
EP4323356A1 (en) 2021-04-13 2024-02-21 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
PE20250118A1 (es) 2021-06-26 2025-01-16 Array Biopharma Inc Inhibidores de mutacion de her2
WO2023081637A1 (en) 2021-11-02 2023-05-11 Enliven Therapeutics, Inc. Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
JP2025509995A (ja) 2022-03-28 2025-04-11 江蘇恒瑞医薬股▲ふん▼有限公司 含窒素複素環系化合物、その調製方法及びその医薬的使用
WO2023195773A1 (ko) * 2022-04-05 2023-10-12 보로노이 주식회사 헤테로아릴 유도체 및 이의 용도
CN117384162A (zh) * 2022-05-17 2024-01-12 浙江文达医药科技有限公司 选择性her2抑制剂
US20240132521A1 (en) 2022-08-22 2024-04-25 Iambic Therapeutics, Inc. Compounds and methods for modulating her2
EP4637773A1 (en) 2022-12-22 2025-10-29 Boehringer Ingelheim International GmbH Crystalline forms of a her2 inhibitor
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024215809A2 (en) * 2023-04-11 2024-10-17 Cogent Biosciences, Inc. Erbb2 inhibitors
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326016A (en) 2023-07-28 2026-03-01 Boehringer Ingelheim Int Process for manufacturing a HER2 inhibitor
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
WO2025034912A2 (en) 2023-08-07 2025-02-13 Cogent Biosciences, Inc. Compounds for fgfr inhibition
CN119320383A (zh) * 2023-09-05 2025-01-17 北京鞍石生物科技股份有限公司 含氮杂芳基化合物及其制备方法和应用
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515988A (ja) 2005-11-15 2009-04-16 アレイ バイオファーマ、インコーポレイテッド 過剰増殖性疾患の処置のためのＥｒｂＢＩ型受容体チロシンキナーゼ阻害剤としてのＮ４−フェニルキナゾリン−４−アミン誘導体および関連化合物
JP2019507170A (ja) 2016-03-01 2019-03-14 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 含窒素ヘテロ環化合物、製造方法、中間体、組成物及び応用
JP2020531553A (ja) 2017-09-01 2020-11-05 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 窒素含有複素環化合物、製造方法、中間体、組成物および使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19608588A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
PL373848A1 (en) 2001-12-12 2005-09-19 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
MXPA06005024A (es) 2003-11-06 2006-07-06 Pfizer Prod Inc Combinaciones de inhibidor de erbb2 selectivo/anticuerpos anti-erbb en el tratamiento del cancer.
MX368464B (es) * 2013-12-05 2019-10-02 Pfizer Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinil o y pirrolo[2,3-d]piridinilo.
EP3143015B1 (en) 2014-05-13 2019-02-20 ARIAD Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN110526912B (zh) 2014-06-19 2023-02-14 武田药品工业株式会社 用于激酶抑制的杂芳基化合物
JP6863901B2 (ja) 2015-05-13 2021-04-28 アリアド ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
CN111032655B (zh) 2017-08-31 2022-09-02 达纳-法伯癌症研究所股份有限公司 Egfr和/或her2抑制剂和使用方法
US11608343B2 (en) * 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
EP4637773A1 (en) * 2022-12-22 2025-10-29 Boehringer Ingelheim International GmbH Crystalline forms of a her2 inhibitor
AU2023410266A1 (en) * 2022-12-22 2025-06-12 Boehringer Ingelheim International Gmbh Solid dispersion of a her2 inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515988A (ja) 2005-11-15 2009-04-16 アレイ バイオファーマ、インコーポレイテッド 過剰増殖性疾患の処置のためのＥｒｂＢＩ型受容体チロシンキナーゼ阻害剤としてのＮ４−フェニルキナゾリン−４−アミン誘導体および関連化合物
JP2019507170A (ja) 2016-03-01 2019-03-14 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 含窒素ヘテロ環化合物、製造方法、中間体、組成物及び応用
JP2020531553A (ja) 2017-09-01 2020-11-05 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド 窒素含有複素環化合物、製造方法、中間体、組成物および使用

Also Published As

Publication number Publication date
EP4100409A1 (en) 2022-12-14
JP2023512174A (ja) 2023-03-24
CN115052878A (zh) 2022-09-13
US20230126204A1 (en) 2023-04-27
CN115052878B (zh) 2024-07-09
EP4100409B1 (en) 2024-08-28
WO2021156178A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
JP7626773B2 (ja) ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
JP7626774B2 (ja) ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
JP7260723B2 (ja) ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン
TWI913256B (zh) 作為ＨＥＲ２抑制劑之[１,３]二基[５,４-ｄ]嘧啶
HK40122799A (en) [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
HK40081106A (en) [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
HK40081106B (en) [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
EA047617B1 (ru) [1,3]ДИАЗИНО[5,4-d]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ HER2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240131

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250123

R150 Certificate of patent or registration of utility model

Ref document number: 7626773

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150